Delhi recorded less than a thousand COVID cases yesterday. It is the lowest number of positive cases recorded in the National Capital in a span of more than a month. A total of 954 new confirmed cases of Coronavirus have been reported in the city during the last twenty four hours taking the total number of cases to 1,23,747. Delhi Government has confirmed that 1,00918 people affected with Coronavirus have been cured so far. In the last 24 hours, 1,784 people recovered and 35 deaths were reported in the National Capital taking the toll to 3,663. Presently, the total number of active corona cases in the national capital is 15,166.

 Speaking to India Today, AIIMS Director Randeep Guleria said today on Monday that Delhi seems to have hit the coronavirus peak with the number of daily cases declining significantly for the past few days. Delhi on Monday registered 954 fresh Covid-19 cases, taking the tally in the national capital to over 1.23 lakh. This was for the first time that fresh cases came in three digits when they were being reported in the range of 1,000-2,000 consecutively.

Randeep Guleria also said cases are increasing in certain states and they will reach a peak later, but there is not much evidence of community transmission of Covid-19 at the national level.

On being asked if coronavirus cases in India have hit the peak, Randeep Guleria said, "My feeling is that certain areas have hit their peak. Delhi seems to have done so because the cases have declined significantly. But certain areas are yet to reach their peak. Cases are increasing in certain states. They will reach a peak later."

Some states in the South, Ahmedabad in Gujarat and the central part of Mumbai also seem to be showing a decline. 

AIIMS Delhi has started the registration process for conducting the human trials of COVAXIN yesterday. Principal Investigator for conducting these trials Dr. Sanjay Rai said that the response for registration on the very first day has been overwhelming. He informed that around 1,800 applicants have forwarded their requests to volunteer for the human trials.

In the first phase of trials at AIIMS, the vaccine indigenously developed by Bharat Biotech will be administered on 100 healthy individuals.Speaking exclusively to AIR, NEWS, Dr. Rai informed that the AIIMS Ethics Committee has formulated stringent protocols ensuring safety of volunteers. He informed that the second phase of the human clinical trial will begin after one month of the commencement of the primary phase. Dr. Rai said that the first dose of the vaccine is likely to be administered to the volunteers on Thursday.
With Inputs from ; www.indiatoday.in